Filing Flows › 10x Genomics (TXG) › Q2 2026 › vs Q2 2025
10x Genomics (TXG) Q2 2026 vs Q2 2025 (year over year)
10x Genomics's revenue fell $21.9M (-13%) from $173M in Q2 2025 to $151M in Q2 2026. The biggest changes: License and royalty revenue −$25.8M (-93%); Products and services revenue +$3.9M (+3%).
10x Genomics, Q2 2026: revenue $151M (-13% year over year), operating margin -12.9%, net loss $17.9M, operating cash flow $17.0M. The chart draws each line against Q2 2025, the increases inside each band.
Margins
| Q2 2026 | Q2 2025 | Change | |
|---|---|---|---|
| Free cash flow margin | 10.2% | 9.3% | +0.9 pts |
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Single Cell | $88.5M | $85.8M | $2.7M | +3% |
| Spatial | $42.3M | $36.4M | $5.9M | +16% |
| Services | $10.7M | $8.5M | $2.2M | +26% |
| Spatial | $4.6M | $8.8M | −$4.2M | -48% |
| Single Cell | $3.1M | $5.7M | −$2.6M | -46% |
| Products and services revenue | $149M | $145M | $3.9M | +3% |
| License and royalty revenue | $1.9M | $27.8M | −$25.8M | -93% |
| Revenue | $151M | $173M | −$21.9M | -13% |
| Other income, net | $910K | $6.9M | −$6.0M | -87% |
| Income tax benefit | $714K | −$2.5M | $3.2M | — |
| Net loss | $17.9M | −$34.5M | $52.5M | — |
| Costs & expenses | $171M | $180M | −$9.2M | -5% |
| Operating costs | $171M | $143M | $27.8M | +19% |
| Cost of revenue | $38.5M | $47.8M | −$9.3M | -19% |
| Operating expenses | $132M | $95.0M | $37.1M | +39% |
| Operating cash sources | $35.3M | $35.4M | −$94K | -0.3% |
| Depreciation & amortization | $9.7M | $7.8M | $1.8M | +24% |
| Share-based compensation | $25.6M | $27.6M | −$1.9M | -7% |
| Net loss absorbed | $17.9M | −$34.5M | $52.5M | — |
| Working capital & other | $375K | $52.2M | −$51.8M | -99% |
| Operating cash flow | $17.0M | $17.7M | −$734K | -4% |
| Free cash flow (OCF − capex) | $15.4M | $16.1M | −$744K | -5% |
| Capital expenditures | $1.6M | $1.6M | $10K | +0.6% |
Questions
How much did 10x Genomics's revenue grow year over year in Q2 2026?
10x Genomics's revenue fell $21.9M (-13%) from $173M in Q2 2025 to $151M in Q2 2026.
What drove 10x Genomics's revenue change in Q2 2026?
License and royalty revenue −$25.8M (-93%); Products and services revenue +$3.9M (+3%).